{"id":8324,"date":"2021-07-28T10:10:46","date_gmt":"2021-07-28T08:10:46","guid":{"rendered":"https:\/\/filinf.it\/?page_id=8324"},"modified":"2024-02-23T16:48:42","modified_gmt":"2024-02-23T15:48:42","slug":"hodgkins-lymphoma","status":"publish","type":"page","link":"https:\/\/filinf.it\/en\/structure\/scientific-commission\/hodgkins-lymphoma\/","title":{"rendered":"Hodgkin’s lymphoma Commission"},"content":{"rendered":"

Hodgkin’s lymphoma<\/a> (HL) is a neoplasm of the\u00a0<\/span>lymphatic system<\/span><\/b>, which arises in the lymphatic tissues and organs (lymph nodes, spleen, bone marrow) and affects the cells (lymphocytes) which have the task of defending the body from infections, from the external agents and from the same neoplastic diseases. The name of the disease is the surname of Sir Thomas Hodgkin who described the disease in 1832.<\/span>\u00a0<\/span><\/p>\n

\"\"<\/p>\n

The primary\u00a0<\/span>goal\u00a0<\/span><\/b>of the Hodgkin’s lymphoma Commission<\/strong> is to optimize the management of patients with H<\/span>L<\/span>\u00a0during the phases of first diagnosis and of replace and refractoriness of the disease through the creation of prospective studies and retrospective collections of ‘real life’ data, involving the largest number of Centers that take care of these patients in Italy.<\/span>\u00a0<\/span><\/p>\n

This goal will be pursued through the development and approval of national and international\u00a0<\/span>study proposals<\/span><\/b>, aimed at comparing\u00a0<\/span>standard therapies with innovative therapeutic strategies in Hodgkin’s lymphoma<\/span><\/b>.<\/span>\u00a0<\/span><\/p>\n

The proposals are:<\/span>\u00a0<\/span><\/p>\n